News

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO.

“We are excited to welcome Dave to our leadership team,” said McCoy. “His deep expertise in pharmaceutical manufacturing and global operations will be instrumental as we continue to bring our Petersburg facility online and expand access to essential medicines.”

Sehgal has nearly 30 years of experience in the pharmaceutical industry, having held leadership roles in the vaccines, biologics and small molecule manufacturing space. He also has significant experience in technical services, quality and process development. Dr. Sehgal succeeds Jay Benson.

“I am thrilled to join Civica at this time in the company’s history,” said Sehgal. “I look forward to leading the team that will bring high-quality, essential generic medicines, manufactured in the United Sates to patients who need them.”

Dr. Sehgal resides in Raleigh, NC and will be working closely with the Civica team at the company’s manufacturing facility in Petersburg, Va. The 140,000 square foot, state-of-the-art facility currently employs more than 200 skilled workers, with plans to hire another 60 employees by the end of 2025. The facility has the capacity to manufacture 90 million vials, 50 million syringes and 120 million pre-filled pens of generic sterile injectable medicines every year. The facility is in the final stages of certification by regulatory authorities and will be producing medicines for distribution in 2026.

Prior to joining Civica, Dr. Sehgal was the Vice President and Global Processing Engineering Head at CSL-Behring in Holly Springs, North Carolina. In that role, he led a team of 500 scientists and engineers across four global sites in support of all CSL-Behring products. Before CSL-Behring, Sehgal held leadership positions at FUJIFILM Diosynth Biotechnologies, Seqirus, Novartis, and Merck. Sehgal earned a bachelor’s, master’s, and doctoral degree in chemical engineering from NC State University.

This appointment reflects Civica’s continued commitment to operational excellence and its mission to make quality generic medicines accessible and affordable for all.

 

Read more here.

Recent News

10/23/2026

PAK BioSolutions and iBET Advance Integrated Continuous AAV8 Purification

PAK BioSolutions today announced the publication of a peer-reviewed study on integrated, continuous purification of adeno-associated virus serotype 8 (AAV8) using the PAK PD™ Process Development Scale Continuous Purification System. Conducted in collaboration with iBET – Instituto de Biologia Experimental e Tecnológica, the study, “Streamlining AAV8 Purification with Cyclic Integrated Capture–Polishing Chromatography,” was published in …

10/22/2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company’s more than $50 …

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …